Investigational drug · Phase 3
Zenagamtide
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Type 2 Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
13
Any phase or sponsor naming "Zenagamtide"
First trial start
2026
Aug 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zenagamtide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Type 2 Diabetes
- Cardiovascular Risk
- Diabetes Mellitus, Type 2
- Chronic Kidney Disease
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Zenagamtide" as an intervention, largest first.
- A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07861100 · 8,500 participants (planned) · Start Oct 26, 2026 · Primary completion Sep 16, 2030
Drug: Zenagamtide; Placebo · For: Cardiovascular Risk; Obesity
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 769 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07797335 · 1,778 participants (planned) · Start Aug 24, 2026 · Primary completion Jul 31, 2028
Drug: Zenagamtide; Insulin glargine U-100 · For: Type 2 Diabetes; Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Montgomery, Alabama · 330 sites in all
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931573 · 1,200 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 4, 2028
Drug: Zenagamtide; Semaglutide and 1 more · For: Type 2 Diabetes
Sites: Phoenix, Arizona; La Jolla, California; La Mesa, California · 230 sites in all
- A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931599 · 1,060 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 24, 2028
Drug: Zenagamtide; Semaglutide and 2 more · For: Diabetes Mellitus, Type 2
Sites: La Jolla, California; Lancaster, California; Lincoln, California · 152 sites in all
- AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07720271 · 950 participants (planned) · Start Aug 31, 2026 · Primary completion Jun 27, 2028
Drug: zenagamtide; Placebo · For: Overweight; Obesity
Sites: Anniston, Alabama; Birmingham, Alabama; Montgomery, Alabama · 41 sites in all
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutidePivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07668414 · 650 participants (planned) · Start Sep 22, 2026 · Primary completion Oct 10, 2028
Drug: Zenagamtide; Semaglutide and 2 more · For: Overweight; Obesity
Sites: Lancaster, California; Palm Springs, California; Pomona, California · 45 sites in all
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931547 · 450 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 31, 2028
Drug: Zenagamtide · For: Type 2 Diabetes; Chronic Kidney Disease
Sites: La Jolla, California; Lancaster, California; Lincoln, California · 125 sites in all
- AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07668401 · 400 participants (planned) · Start Jan 7, 2027 · Primary completion Jan 11, 2029
Drug: Zenagamtide; Placebo ( matched to Zenagamtide) · For: Obesity; Overweight
Sites: Surat, India; Vadodara, India; Hubbali, India · 44 sites in all
- A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07815067 · 320 participants (planned) · Start Sep 7, 2026 · Primary completion Jun 12, 2028
Drug: Zenagamtide injection; Zenagamtide tablet · For: Overweight; Obesity
Sites: Berlin, Germany
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExercisePivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931495 · 200 participants (planned) · Start Nov 10, 2026 · Primary completion Jun 5, 2028
Drug: Zenagamtide; Placebo · For: Diabetes Mellitus, Type 2
Sites: Fountain Valley, California; Los Angeles, California; Spring Valley, California · 48 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
Rubin R · JAMA 2026
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Panou T, Gouveri E, Popovic DS, et al. · Diabetes Ther 2026
- Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.
Oldenburg LIK, Haugaard SP, Karlsson T, et al. · Diabetes Obes Metab 2026
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Alhazmi A, le Roux CW · Diabetes Obes Metab 2026
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Mora P, Aroda VR, Asong M, et al. · Lancet 2026
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Mora P, Aroda VR, Asong M, et al. · Lancet 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.